title: Application of liposomal technologies for delivery of platinum analogs in oncology.
abstract: Platinum-based chemotherapy, such as cisplatin, oxaliplatin, and carboplatin, is one of the most widely utilized classes of cancer therapeutics. While highly effective, the clinical applications of platinum-based drugs are limited by their toxicity profiles as well as suboptimal pharmacokinetic properties. Therefore, one of the key research areas in oncology has been to develop novel platinum analog drugs and engineer new platinum drug formulations to improve the therapeutic ratio further. Such efforts have led to the development of platinum analogs including nedaplatin, heptaplatin, and lobaplatin. Moreover, reformulating platinum drugs using liposomes has resulted in the development of L-NDPP (Aroplatin™), SPI-77, Lipoplatin™, Lipoxal™, and LiPlaCis®. Liposomes possess several attractive biological activities, including biocompatibility, high drug loading, and improved pharmacokinetics, that are well suited for platinum drug delivery. In this review, we discuss the various platinum drugs and their delivery using liposome-based drug delivery vehicles. We compare and contrast the different liposome platforms as well as speculate on the future of platinum drug delivery research.
authors.affiliation: Department of Chemistry, University of Chicago, Chicago, IL, USA.
authors.forename: Demin
authors.initials: D
authors.lastname: Liu
authors.forename: Chunbai
authors.initials: C
authors.lastname: He
authors.forename: Andrew Z
authors.initials: AZ
authors.lastname: Wang
authors.forename: Wenbin
authors.initials: W
authors.lastname: Lin
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry; D004339:Drug Compounding / Q000379:methods; D006801:Humans; D008081:Liposomes / Q000737:chemistry*; D053769:Nanocapsules / Q000737:chemistry* / Q000648:ultrastructure*; D009369:Neoplasms / Q000188:drug therapy*; D010316:Particle Size; D017671:Platinum Compounds / Q000008:administration & dosage* / Q000737:chemistry*
chemical_list: D000970:Antineoplastic Agents; D008081:Liposomes; D053769:Nanocapsules; D017671:Platinum Compounds
keywords: cancer; drug delivery; liposome; platinum analog
references.citation: Anticancer Drugs. 1999 Nov;10(10):911-20
references.pmid: 10630359
references.citation: Cancer Chemother Pharmacol. 2002 Mar;49(3):201-10
references.pmid: 11935212
references.citation: Cancer Chemother Pharmacol. 2004 Apr;53(4):329-36
references.pmid: 14673619
references.citation: Cancer Res. 1990 Jul 15;50(14):4254-9
references.pmid: 2364384
references.citation: Cancer Chemother Pharmacol. 1989;24(1):1-8
references.pmid: 2720887
references.citation: Nanoscale Res Lett. 2013 Feb 22;8(1):102
references.pmid: 23432972
references.citation: Br J Cancer. 2006 Oct 9;95(7):822-8
references.pmid: 16969346
references.citation: J Control Release. 2011 Jul 30;153(2):187-94
references.pmid: 21501640
references.citation: Cancer Res. 1998 Aug 1;58(15):3320-30
references.pmid: 9699662
references.citation: Cancer Chemother Pharmacol. 2011 Oct;68(4):945-50
references.pmid: 21301848
references.citation: Lancet. 1974 Jun 29;1(7870):1313-6
references.pmid: 4134296
references.citation: FEBS Lett. 1990 Jul 30;268(1):235-7
references.pmid: 2384160
references.citation: Anticancer Res. 2006 Mar-Apr;26(2B):1489-93
references.pmid: 16619562
references.citation: J Mol Biol. 1965 Aug;13(1):238-52
references.pmid: 5859039
references.citation: Vet Comp Oncol. 2008 Mar;6(1):1-18
references.pmid: 19178659
references.citation: Biochim Biophys Acta. 1990 Jun 27;1025(2):143-51
references.pmid: 2364073
references.citation: J Antimicrob Chemother. 1996 Jul;38(1):145-50
references.pmid: 8858467
references.citation: Cancer Res. 1992 May 1;52(9):2431-9
references.pmid: 1568213
references.citation: Biochim Biophys Acta. 2003 Jan 10;1609(1):95-101
references.pmid: 12507763
references.citation: Expert Opin Investig Drugs. 2009 Aug;18(8):1197-218
references.pmid: 19604121
references.citation: Ann Oncol. 2001 Apr;12(4):493-6
references.pmid: 11398881
references.citation: Int J Cancer. 2004 Jun 20;110(3):352-61
references.pmid: 15095299
references.citation: J Clin Oncol. 1990 Nov;8(11):1777-81
references.pmid: 1700077
references.citation: Chem Rev. 1999 Sep 8;99(9):2451-66
references.pmid: 11749486
references.citation: Anticancer Res. 2010 Feb;30(2):541-5
references.pmid: 20332467
references.citation: Cancer Res. 2002 Aug 1;62(15):4282-8
references.pmid: 12154030
references.citation: Chem Commun (Camb). 2012 Mar 7;48(20):2630-2
references.pmid: 22286522
references.citation: Anticancer Res. 2004 Jul-Aug;24(4):2193-200
references.pmid: 15330160
references.citation: J Microencapsul. 2012;29(3):262-76
references.pmid: 22208705
references.citation: Ann Oncol. 2000 Aug;11(8):1029-33
references.pmid: 11038041
references.citation: J Am Chem Soc. 2006 Jul 19;128(28):9024-5
references.pmid: 16834362
references.citation: Chem Rev. 2007 May;107(5):1387-407
references.pmid: 17455916
references.citation: Nanomedicine (Lond). 2012 Oct;7(10):1577-90
references.pmid: 23148540
references.citation: Cancer Chemother Pharmacol. 1992;30(5):365-9
references.pmid: 1505075
references.citation: J Am Chem Soc. 2008 Sep 3;130(35):11584-5
references.pmid: 18686947
references.citation: Cancer Chemother Pharmacol. 1982;9(3):140-7
references.pmid: 6761010
references.citation: Curr Biol. 1999 Mar 11;9(5):273-6
references.pmid: 10074455
references.citation: Biochim Biophys Acta. 1993 Sep 19;1151(2):201-15
references.pmid: 8373796
references.citation: Chemother Res Pract. 2011;2011:843019
references.pmid: 22312559
references.citation: Nat Med. 2002 Jan;8(1):81-4
references.pmid: 11786911
references.citation: Ann Oncol. 2007 Jul;18(7):1159-64
references.pmid: 17229768
references.citation: J Mater Chem. 2012 Jan 1;22(35):18139-18144
references.pmid: 23049169
references.citation: Biochemistry. 1997 Jan 7;36(1):66-75
references.pmid: 8993319
references.citation: Angew Chem Int Ed Engl. 2008;47(40):7722-5
references.pmid: 18767098
references.citation: Am J Vet Res. 2004 Nov;65(11):1474-8
references.pmid: 15566083
references.citation: Chem Commun (Camb). 2012 Mar 11;48(21):2668-70
references.pmid: 22428170
references.citation: Dalton Trans. 2010 Sep 21;39(35):8113-27
references.pmid: 20593091
references.citation: J Clin Oncol. 2001 Mar 1;19(5):1444-54
references.pmid: 11230490
references.citation: Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11460-4
references.pmid: 1763060
references.citation: J Biol Chem. 1994 Feb 4;269(5):3198-204
references.pmid: 8106354
references.citation: Cancer Res. 1988 Aug 15;48(16):4509-12
references.pmid: 3396003
references.citation: Cancer Chemother Pharmacol. 1996;37(5):435-44
references.pmid: 8599866
references.citation: Angew Chem Int Ed Engl. 2011 Apr 11;50(16):3696-700
references.pmid: 21416573
references.citation: Ann Oncol. 1998 Jul;9(7):711-6
references.pmid: 9739435
references.citation: Eur J Cancer. 2010 Nov;46(16):3016-21
references.pmid: 20801016
references.citation: Chem Sci. 2012;3(1):
references.pmid: 24288587
references.citation: Nature. 1965 Feb 13;205:698-9
references.pmid: 14287410
references.citation: Int J Cancer. 2003 Jul 1;105(4):561-7
references.pmid: 12712451
references.citation: Cancer Res. 2002 Dec 15;62(24):7190-4
references.pmid: 12499256
references.citation: J Control Release. 2012 Jun 10;160(2):117-34
references.pmid: 22484195
references.citation: Biochim Biophys Acta. 1979 Oct 19;557(1):9-23
references.pmid: 95096
references.citation: Nat Rev Cancer. 2007 Aug;7(8):573-84
references.pmid: 17625587
references.citation: Cancer Chemother Pharmacol. 2006 Dec;58(6):759-64
references.pmid: 16847673
references.citation: Cancer Chemother Pharmacol. 1999;43(1):1-7
references.pmid: 9923534
references.citation: Nat Rev Drug Discov. 2005 Apr;4(4):307-20
references.pmid: 15789122
references.citation: Cancer Res. 1987 Dec 15;47(24 Pt 1):6462-6
references.pmid: 3315188
references.citation: Anticancer Res. 2005 Jul-Aug;25(4):3031-9
references.pmid: 16080562
references.citation: Biochim Biophys Acta. 2004 Oct 11;1665(1-2):134-41
references.pmid: 15471579
references.citation: J Drug Deliv. 2012;2012:581363
references.pmid: 21904682
references.citation: Adv Drug Deliv Rev. 2011 Mar 18;63(3):129-30
references.pmid: 20457195
references.citation: Nat Rev Clin Oncol. 2010 Nov;7(11):653-64
references.pmid: 20838415
references.citation: RSC Adv. 2013 Sep 14;3(34):14438-14443
references.pmid: 24058727
references.citation: J Control Release. 2001 Jul 6;74(1-3):47-61
references.pmid: 11489482
references.citation: Int J Pharm. 2008 Jan 4;346(1-2):143-50
references.pmid: 17640835
references.citation: Br J Cancer. 2001 Apr 20;84(8):1029-35
references.pmid: 11308249
references.citation: Oncol Rep. 2004 Jul;12(1):3-12
references.pmid: 15201951
references.citation: ACS Nano. 2011 Nov 22;5(11):8649-55
references.pmid: 21961944
references.citation: Cancer Res. 1994 Feb 15;54(4):987-92
references.pmid: 8313389
references.citation: Eur J Cancer. 1998 Sep;34(10):1522-34
references.pmid: 9893623
references.citation: Cancer Chemother Pharmacol. 1988;22(3):223-7
references.pmid: 3409456
references.citation: Cancer Res. 1993 Apr 1;53(7):1484-8
references.pmid: 8453612
references.citation: Adv Drug Deliv Rev. 2013 Jan;65(1):36-48
references.pmid: 23036225
references.citation: Chem Soc Rev. 2013 Jan 7;42(1):202-24
references.pmid: 23042411
references.citation: Cancer Res. 1993 Oct 15;53(20):4913-9
references.pmid: 8402681
references.citation: Nat Rev Drug Discov. 2005 Feb;4(2):145-60
references.pmid: 15688077